Dr. Thomas Joseph Kaley, MD

Dr. Kaley practices at Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center.

Dr. Kaley's NPI, 1578721858, was assigned on May 23, 2008. Dr. Kaley graduated from New York University School of Medicine in 2003. Dr. Kaley's New York license number on file is 233620.

Dr. Kaley's primary practice is Memorial Sloan Kettering Cancer Center, at 1275 York Avenue, New York, NY 10065.

Dr. Kaley's primary practice is Memorial Sloan Kettering Cancer Center in New York, New York, part of Memorial Sloan Kettering Cancer Center. The medical group on file is Memorial Sloan Kettering Cancer Center. Dmand AI also links Dr. Kaley to 2 more medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kaley practices. Vendor and product names are available with a free account.

Neurology is Dr. Kaley's primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Kaley is board certified in neurology by the American Board of Psychiatry and Neurology. Dmand AI has Dr. Kaley's licenses on file in 2 states: New York and New Jersey.

Dmand AI lists epilepsy, neuropathy and thoracic spine disorders among the conditions Dr. Kaley treats.

CMS data shows 310 Medicare services from Dr. Kaley across 4 procedure codes in 2024, for 226 Medicare patients. Medicare paid $36,674 for them.

CMS counts 226 Medicare patients who saw Dr. Kaley in 2024. The largest group is 65 to 74, with 106 patients. 73% of them have high cholesterol, and 69% have high blood pressure. 16% are also on Medicaid. Their average risk score is 2.04, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Kaley's median patient age at 69, with 59% women.

In 2024, Dr. Kaley wrote 112 Medicare Part D claims for 45 patients. 96% of them were for generic drugs. CMS names the drug for 53 of them, across 4 drugs with 11 or more claims each, at $457 in total drug cost. In 2023, CMS named 43 claims across 3 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 82 out of 100 for Dr. Kaley for performance year 2024, reported as part of a group. Dr. Kaley accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kaley as offering telehealth.

Dmand AI links 73 papers to Dr. Kaley, published from 2012 to 2025. 2018 was the busiest year, with 8. The most frequent topics are Brain Neoplasms, Glioblastoma and Glioma. Dr. Kaley has published most often in Neuro Oncol. Dr. Kaley's most frequent co-authors are Craig P. Nolan, MD, Antonio Marcilio Padula Omuro, MD and Elena Pentsova, MD.

Dmand AI links Dr. Kaley to 10 clinical trials, 4 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Glioblastoma, Meningioma and Oligodendroglioma. Memorial Sloan Kettering Cancer Center sponsors the most, 6.

CMS Open Payments shows 5 general payments to Dr. Kaley from 3 drug and device companies from 2017 to 2025. Consulting fees make up the largest share, 69% of the total. Servier Pharmaceuticals LLC paid the most, $5,518. It also lists 1 research payment totaling $78,850 in 2018.

Dr. Kaley graduated from New York University School of Medicine in 2003.

Dr. Kaley is in network with 14 carriers, including Aetna, Excellus BlueCross BlueShield and Elevance. PPO plans come from the most carriers, 9. Check the plan with the practice before a visit.